Effect of vinpocetine combined with butylphthalide and rosuvastatin on cerebral vascular reserve and serum CRP and MMP-9 in patients with acute cerebral infarction
Objective:To observe the effects of vinpocetine combined with butylphthalide and rosuvastatin on the cerebrovascular reserve capacity and serum levels of C-reactive protein(CRP)and matrix metalloproteinase-9(MMP-9)in patients with acute cerebral infarction(ACI).Method:Eighty patients with ACI who received treatment in our hospital from August 2022 to May 2023 were randomly divided into a dual-drug group and a triple-drug group(n=40).The dual-drug group received intravenous administration of 100 mL of butylphthalide and oral administration of 20 mL of rosuvastatin daily,while the triple-drug group received intravenous administration of 20 mL of vinpocetine in addition to the above treatments.Both groups underwent a treatment course of 2 weeks.Before and after treatment,transcranial Doppler(TCD)breath-holding test was used to examine cerebrovascular reserve capacity(CVR),including arterial flow velocity(MFV),breath-holding index(BHI),and pulsatility index(PI).Serum CRP levels were measured using a biochemical analyzer,and serum MMP-9 levels were detected using enzyme-linked immunosorbent assay.At the same time,the improvement of symptoms and the incidence of adverse reactions were compared.Results:The levels of CVR,MFV,and BHI in the triple-drug group were significantly higher than those in the dual-drug group,while the level of PI in the triple-drug group was significantly lower than that in the dual-drug group(P<0.05).The levels of serum CRP and MMP-9 in the triple-drug group were lower than those in the dual-drug group(P<0.05).The total effective rate in the triple-drug group was significantly higher than that in the dual-drug group(P<0.05).The incidence of adverse reactions in the triple-drug group was comparable to that in the dual-drug group(P>0.05).Conclusion:Vinpocetine combined with butylphthalide and rosuvastatin can significantly improve CVR in patients with ACI,reduce the levels of inflammatory factors CRP and MMP-9,and have significant efficacy and good safety.
NETL
NSTL
万方数据
